Hypercholesterolemia

08/15/2007 - "Leading analogs demonstrated potent inhibition of cholesterol synthesis in both in vitro and in vivo models and may be useful for the treatment of hypercholesterolemia and related lipid disorders."
01/01/2000 - "Since the unfavorable impact of hypercholesterolemia on the cardiovascular system has been proven, effective, inexpensive and easy to use cholesterol-lowering treatment options have been looked for. "
10/01/1993 - "Meta-analysis of the controlled trials of garlic to reduce hypercholesterolemia showed a significant reduction in total cholesterol levels. "
05/01/2015 - "Patients with mild hypercholesterolemia receiving short-chain FOS 10.6g daily presented no statistically significant reduction in serum cholesterol levels. "
08/01/2004 - "These results demonstrate that increased expression of G5 and G8 attenuates diet-induced hypercholesterolemia in Ldlr-/- mice, resulting in a significant reduction in plasma levels of cholesterol and aortic atherosclerotic lesion area."

06/01/2010 - "Our findings support claims that simvastatin may be beneficial in preserving endothelial function in prediabetic subjects with normo- or mild-to-moderate hypercholesterolemia. "
10/16/1989 - "Simvastatin appears to be an effective and well-tolerated agent for the treatment of primary hypercholesterolemia and, as further study confirms long-term safety and efficacy, it should become a useful addition to the therapeutic armamentarium."
12/01/1999 - "Simvastatin therapy for 12 months is well tolerated and effective for both women and men with hypercholesterolemia. "
05/01/1997 - "We found that low-dose simvastatin therapy is effective in achieving long-term decreases in serum lipid levels and is well tolerated by patients with moderate hypercholesterolemia. "
11/01/1995 - "They further indicate that once-daily treatment with simvastatin is effective in patients with isolated hypercholesterolemia or hypercholesterolemia associated with elevated triglyceride levels."

06/01/2012 - "Though this case series is limited by small sample size, study duration, and lack of control group, the product's significant reduction in LDL cholesterol without severe side effects indicates that this product may be a clinically effective and well tolerated alternative treatment to using statin medications to treat hypercholesterolemia."
11/15/2015 - "Vyto10, Vyto20, and Simva20 showed significant reduction of LDL cholesterol levels and improvement of flow-mediated dilation in patients with hypercholesterolemia. "
02/01/2015 - "The relative changes in total and LDL cholesterol were significantly greater for subjects with severe hypercholesterolemia (>6.6 mmol/L) than those with moderate hypercholesterolemia (5.2-6.6 mmol/L). "
06/01/2011 - "Baseline and follow-up evaluations showed improvement in hypercholesterolemia and high LDL cholesterol levels in cases versus controls. "
06/01/1992 - "The findings suggest that the significant reduction in serum LDL cholesterol levels in patients with CHD concurrent with hypercholesterolemia who take hypolipidemic therapy is followed by a decrease in the atherogenic potential."

06/01/1997 - "Atorvastatin is highly effective and well tolerated in patients with primary hypercholesterolemia with no increased risk of adverse events."
12/01/2010 - "Hypercholesterolemia treatment with 10 mg, fixed dosage of atorvastatin was effective in three quarters of the subjects during the first 6-month treatment; however, a significant number of patients with high LDL-C levels and/or BMI require higher starting and maintenance dosage."
06/20/2007 - "Atorvastatin therapy is beneficial in decreasing oxidative stress related with hypercholesterolemia, mainly affecting lipid profile and PON1 activity."
10/01/2008 - "We previously reported that glycemic control deteriorated in patients receiving atorvastatin, which is useful for the treatment of hypercholesterolemia in patients with type 2 diabetes. "
03/01/2002 - "In hypercholesterolemia patients, atorvastatin 10 mg every other day is safe and effective in lowering TC, TG, with LDL-c and a slight increase in HDL-c."

06/14/1993 - "Pravastatin treatment of hypercholesterolemia is highly effective and well tolerated alone and in combination with bile acid-binding resin and shows no tendency to increase muscle enzyme levels."
09/01/1994 - "These results indicate that long-term administration of pravastatin is beneficial in the treatment of hypercholesterolemia in elderly patients."
05/01/1996 - "This combination may be useful and more cost-effective in elderly patients with hypercholesterolemia, who might have a higher incidence of side effects when using larger doses of pravastatin alone."
12/01/1990 - "Once-daily pravastatin is a safe and effective treatment for patients with primary hypercholesterolemia and has a favorable safety profile."
06/01/1994 - "In this study, pravastatin was well tolerated and effective in lowering LDL-C, Total-C, and TG and in raising HDL-C during long-term treatment of elderly patients with primary hypercholesterolemia."

08/01/2004 - "Coadministration of ezetimibe + statin offers a well-tolerated, highly efficacious new treatment strategy for patients with hypercholesterolemia."
01/01/2012 - "Ezetimibe added to ongoing statin therapy resulted in significantly greater lipid-lowering compared with doubling the dose of statin in Taiwanese patients with hypercholesterolemia. "
01/01/2009 - "Furthermore, ezetimibe add-on therapy improved vascular endothelial function in high-risk patients with hypercholesterolemia. "
05/01/2003 - "These studies establish ezetimibe as an effective lipid-lowering agent, which will likely be useful in the management of a broad range of patients with hypercholesterolemia. "
01/01/2011 - "Therefore, the objective in this study was to clarify the vascular protective effects of ezetimibe in patients with hypercholesterolemia. "

07/01/2015 - "The purpose of this study was to further characterize the effects of H2-rich water (0.9 L/day) on the content, composition, and biological activities of plasma lipoproteins on patients with hypercholesterolemia and their underlying mechanisms in a double-blinded, randomized, and placebo-controlled trial. "
02/01/2012 - "Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo."
04/28/2006 - "In this study, we show that endothelial Kir channels are suppressed by hypercholesterolemic levels of lipoproteins in vitro and by serum hypercholesterolemia in vivo. "
07/01/1982 - "Dietinduced and physiologically occurring hypercholesterolemias in the spontaneous hypothyroid European badger (Meles meles L.): a density gradient study of lipoprotein profile."
07/01/1982 - "Diet-induced and physiologically occurring hypercholesterolemias in the spontaneous hypothyroid European badger (Meles meles L.): a density gradient study of lipoprotein profile."

01/01/1988 - "Lovastatin is highly effective in the treatment of primary hypercholesterolemia and represents an important therapeutic advance. "
11/28/1986 - "In this study, lovastatin was a well tolerated and effective agent for the treatment of nonfamilial hypercholesterolemia."
04/01/2002 - "Our results suggest a mechanism by which hypercholesterolemia may increase risk for AD and indicate that lovastatin reduces Abeta formation and may thereby be effective in delaying the onset and/or slowing the progression of AD."
04/05/1995 - "The increase in HDL-C associated with lovastatin lowered cost-effectiveness ratios by approximately 40%, such that the treatment of hypercholesterolemia was relatively cost-effective for men (as low as $20,882 per year of life saved at age 50 years) and women ($36,627 per year of life saved at age 60 years) with additional risk factors. "
01/01/2002 - "Because lovastatin is efficiently extracted by the liver and because its administration in divided doses is associated with increased efficacy, an extended-release (ER) formulation may have the potential for a dose-sparing advantage relative to the immediate-release (IR) formulation in the treatment of hypercholesterolemia. "

02/20/2012 - "We have reported that hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), which are used for treatment of hypercholesterolemia, activate PPARγ and mediate anti-atherogenic effects through PPARγ activation in macrophages. "
09/01/1996 - "A reductase inhibitor, over 26 weeks in patients with primary hypercholesterolemia. "
12/25/1987 - "3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia."
03/01/1985 - "[Determination of the serum enzyme and dehydrogenase activity of circulating lymphocytes during hemosorption in dietary hypercholesterolemia]."
12/01/2013 - "Statins, also known as HMGCoA reductase inhibitors, are frequently used for the treatment of hypercholesterolemia and for the prevention of morbidity and mortality associated with cardiovascular disease. "

04/01/2011 - "Rosuvastatin is a potent statin that appears to be well tolerated and effective in HIV-infected patients with hypercholesterolemia. "
07/15/2004 - "Thus, our findings suggest that treatment with rosuvastatin in patients with hypercholesterolemia may lead to a significant reduction in plasma ADMA levels, which appear to be related to the improvement in endothelial function by rosuvastatin."
11/01/2007 - "In conclusion, long-term treatment with rosuvastatin 40 mg is safe and effective in patients with severe hypercholesterolemia."
08/01/2013 - "This study examined whether the ABCG2 421C>A polymorphism and variants in other genes potentially related to the pharmacokinetics of rosuvastatin influenced the plasma concentration of rosuvastatin in Chinese patients with hypercholesterolemia. "
01/01/2011 - "Published studies randomized trials with rosuvastatin treatment for at least 4 weeks in hypercholesterolemia patients were used for model building and validation. "

09/01/2002 - "LDL apheresis using the DALI system is highly efficacious for the treatment of hypercholesterolemia. "
01/01/1994 - "[Biological efficacy of LDL apheresis in major hypercholesterolemia]."
12/01/1995 - "These findings suggest that LDL-apheresis, when performed before and after PTCA, is effective in preventing restenosis of coronary artery lesions in patients with CHD and hypercholesterolemia."
01/01/2002 - "LDL Apheresis: an effective and safe treatment for refractory hypercholesterolemia."
11/01/2010 - "A single LDL apheresis does not evoke sympathetic overactivation but improved deranged cardiovagal heart rate modulation in hypercholesterolemia."

08/30/2005 - "Use of venous graft was an independent predictor of failure in the study group, whereas hypercholesterolemia was associated with graft failure in both series. "
09/01/2003 - "The present study was undertaken to examine the influence of hypercholesterolemia and acute graft rejection (AGR) episodes on graft function and graft loss due to chronic nephropathy. "
01/01/2001 - "We conducted this study to evaluate the prevalence, and risk factors of hypercholesterolemia (HC) in renal transplant population. "
08/15/2000 - "In this study, we investigated the possible role of hypercholesterolemia in the incidence of chronic kidney graft loss. "
07/01/1999 - "The results of this study suggest that in the presence of hypercholesterolemia, the pathophysiological processes involved in the vein graft are similar to those reported for noncholesterol-fed animals. "

01/01/2004 - "The study group included 6 patients with primary hypercholesterolemia unresponsive to maximal drug therapy. "
06/01/2015 - "Polymorphisms in the PCSK genes have been reported to associate with human diseases and phenotypes, including hypercholesterolemia and blood pressure (BP), and targeting PCSKs is considered a promising future form of drug therapy. "
01/01/2015 - "Recently, dietary changes associated with drug therapy have garnered attention as novel drugs to mitigate or ameliorate hypercholesterolemia. "
09/01/2014 - "We conducted a retrospective cohort analysis utilizing laboratory results of lipid profiles and medical claims from January 2007 to September 2011 to identify patients with elevated LDL-C and diagnoses of hypercholesterolemia without prior pharmacotherapy. "
01/01/2012 - "New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia."

04/01/1999 - "We attempt in this study to determine the prevalence, and evaluate severity and treatment of hypercholesterolemia in kidney transplant recipients. "
05/01/2009 - "Hypercholesterolemia is a common problem among transplant recipients. "
09/01/2007 - "Combined cardiohepatic transplantation due to severe heterozygous familiar hypercholesteremia type II: first case in Argentina--a case report."
01/01/2007 - "In addition to MI and rapid pacing, nerve sprouting and heterogeneous sympathetic hyperinnervation may also be induced by radiofrequency ablation, hypercholesterolemia, and stem cells transplantation. "
01/01/2005 - "We studied effects of neonatal hepatocytes transplantation (NHT) on lipid metabolism and hemostasis in experimental hypercholesterolemia. "

12/01/2005 - "The seemingly protective effects of white ethnicity compared to nonwhite ethnicity, hormone replacement therapy, hypercholesterolemia, and diabetes in the etiology of SAH are uncertain."
06/01/2002 - "The efficacy of dietary intervention alone or combined with hormone replacement therapy in postmenopausal women with hypercholesterolemia in Seoul, Korea."
06/01/2000 - "This study compares the effects of long-term hormone replacement therapy on the lipid profile of postmenopausal women with or without hypercholesterolemia, with a comparison of 2 different regimens over a 3-year period. "
12/01/2005 - "Risk reductions were found for hormone replacement therapy (RR, 0.6 [0.2 to 1.5]; OR, 0.6 [0.4 to 0.8]), hypercholesterolemia (RR, 0.8 [0.6 to 1.2]; OR, 0.6 [0.4 to 0.9]), and diabetes (RR, 0.3 [0 to 2.2]; OR, 0.7 [0.5 to 0.8]). "
04/01/1999 - "In those women, hormone replacement therapy may be proposed in the treatment of postmenopausal hypercholesterolemia."